NMTC vs RMTI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
NMTC presents a contradictory profile with a stable Piotroski F-Score of 6/9 and a very strong liquidity position (Current Ratio 6.41), yet it suffers from severe operational decay. The company is experiencing negative revenue growth (-11.70% YoY) and deep losses, evidenced by an ROE of -146.27%. While the balance sheet is clean with minimal debt (D/E 0.04), the bearish technical trend and consistent lack of profitability make it a high-risk speculative play.
RMTI exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across profitability and operational efficiency. Despite a strong current ratio of 3.98 and low debt-to-equity, the company is suffering from a significant revenue contraction of -25.60% YoY and consistent earnings misses (0/4 beats in the last year). The disconnect between the analyst target price of $3.00 and the actual fundamental decay, coupled with bearish insider selling, suggests a high-risk speculative profile.
Compare Another Pair
Related Comparisons
NMTC vs RMTI: Head-to-Head Comparison
This page compares NeuroOne Medical Technologies Corporation (NMTC) and Rockwell Medical, Inc. (RMTI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.